IL315078A - RNAI constructs for inhibiting PNPLA3 expression and methods for using them - Google Patents
RNAI constructs for inhibiting PNPLA3 expression and methods for using themInfo
- Publication number
- IL315078A IL315078A IL315078A IL31507824A IL315078A IL 315078 A IL315078 A IL 315078A IL 315078 A IL315078 A IL 315078A IL 31507824 A IL31507824 A IL 31507824A IL 315078 A IL315078 A IL 315078A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- rnai constructs
- pnpla3 expression
- inhibiting pnpla3
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01051—1-Acylglycerol-3-phosphate O-acyltransferase (2.3.1.51)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01004—Phospholipase A2 (3.1.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/0104—Orsellinate-depside hydrolase (3.1.1.40)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263322845P | 2022-03-23 | 2022-03-23 | |
| PCT/US2023/064765 WO2023183801A2 (en) | 2022-03-23 | 2023-03-21 | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315078A true IL315078A (en) | 2024-10-01 |
Family
ID=88102183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315078A IL315078A (en) | 2022-03-23 | 2023-03-21 | RNAI constructs for inhibiting PNPLA3 expression and methods for using them |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250207138A1 (https=) |
| EP (1) | EP4496893A2 (https=) |
| JP (1) | JP2025512771A (https=) |
| KR (1) | KR20240162559A (https=) |
| CN (1) | CN118891364A (https=) |
| AR (1) | AR128877A1 (https=) |
| AU (1) | AU2023237880A1 (https=) |
| CA (1) | CA3254112A1 (https=) |
| CL (1) | CL2024002802A1 (https=) |
| IL (1) | IL315078A (https=) |
| MX (1) | MX2024011595A (https=) |
| TW (1) | TW202345869A (https=) |
| WO (1) | WO2023183801A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025252063A1 (zh) * | 2024-06-04 | 2025-12-11 | 正大天晴药业集团股份有限公司 | 靶向pnpla3的双链核糖核酸 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2976445A1 (en) * | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| TW202542311A (zh) * | 2018-09-19 | 2025-11-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
-
2023
- 2023-03-21 IL IL315078A patent/IL315078A/en unknown
- 2023-03-21 JP JP2024555941A patent/JP2025512771A/ja active Pending
- 2023-03-21 CN CN202380028634.5A patent/CN118891364A/zh active Pending
- 2023-03-21 KR KR1020247034728A patent/KR20240162559A/ko active Pending
- 2023-03-21 CA CA3254112A patent/CA3254112A1/en active Pending
- 2023-03-21 EP EP23775843.8A patent/EP4496893A2/en active Pending
- 2023-03-21 WO PCT/US2023/064765 patent/WO2023183801A2/en not_active Ceased
- 2023-03-21 AU AU2023237880A patent/AU2023237880A1/en active Pending
- 2023-03-21 US US18/848,796 patent/US20250207138A1/en active Pending
- 2023-03-23 TW TW112110948A patent/TW202345869A/zh unknown
- 2023-03-23 AR ARP230100734A patent/AR128877A1/es unknown
-
2024
- 2024-09-17 CL CL2024002802A patent/CL2024002802A1/es unknown
- 2024-09-20 MX MX2024011595A patent/MX2024011595A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118891364A (zh) | 2024-11-01 |
| MX2024011595A (es) | 2024-11-08 |
| US20250207138A1 (en) | 2025-06-26 |
| AU2023237880A1 (en) | 2024-09-12 |
| TW202345869A (zh) | 2023-12-01 |
| CL2024002802A1 (es) | 2025-02-07 |
| AR128877A1 (es) | 2024-06-19 |
| JP2025512771A (ja) | 2025-04-22 |
| KR20240162559A (ko) | 2024-11-15 |
| EP4496893A2 (en) | 2025-01-29 |
| WO2023183801A2 (en) | 2023-09-28 |
| WO2023183801A3 (en) | 2023-11-02 |
| CA3254112A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019709D0 (en) | Anti-Coronavirus antibodies and methods of use | |
| IL288398A (en) | rnai constructs to prevent scap expression and methods for using them | |
| IL312348A (en) | HIF-2ALPHA inhibitors and methods of using it | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL316619A (en) | PI3Kα inhibitors and methods of using them | |
| IL314320A (en) | Compounds and methods of use | |
| IL321357A (en) | KIF18A inhibitors and their uses | |
| IL292860B1 (en) | EGFR allosteric inhibitors and methods of using them | |
| IL318393A (en) | Azaquinazoline compounds and methods of use | |
| IL315078A (en) | RNAI constructs for inhibiting PNPLA3 expression and methods for using them | |
| SI4192814T1 (sl) | Zaviralci transglutaminaz | |
| IL317288A (en) | Inhibitors of expression and/or function | |
| IL318694A (en) | Antibodies against CCR8 and methods of using them | |
| IL317825A (en) | RNA interference constructs and methods for inhibiting fam13a expression | |
| IL314277A (en) | Anti-B7-H3 compounds and methods of use | |
| SI4192813T1 (sl) | Zaviralci transglutaminaz | |
| IL316643A (en) | RNA interference constructs for inhibiting scap expression and methods for using them | |
| IL300104A (en) | Antibody specific for mucin-1 and methods of using it | |
| IL321194A (en) | RNA interference constructs for inhibiting TTR expression and methods for using them | |
| IL311839A (en) | RNA interference constructs to inhibit gpam expression and methods for using them | |
| HK40091690A (en) | Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof | |
| HK40115744A (en) | Rnai constructs for inhibiting gpam expression and methods of use thereof | |
| HK40129741A (en) | Rnai constructs for inhibiting ttr expression and methods of use thereof | |
| CA3276645A1 (en) | Rnai constructs for inhibiting ttr expression and methods of use thereof | |
| GB202119051D0 (en) | Wingsail and method of use |